The case of insulin analogue is didactic for this relation between judicialization and incorporation, since, after two negative stances on incorporation in 2014, the Comissão Nacional de Incorporação de Tecnologias no SUS (Conitec – National Commission for Incorporation of Technologies in SUS), recommended the incorporation of fast-acting insulins by SUS for the treatment of type 1 diabetes mellitus (DM1) in 2017, and, in March 2019, a new, favorable opinion was issued in favor of long-acting insulin analogue for DM1, even without new scientific evidence of superiority. This evidence concerns the gene INS and type 1 diabetes mellitus.